| Position 2008 (2007) | Company | No of R&D products 2008 (2007) | No of own products |
|---|---|---|---|
| 1 (1) | GlaxoSmithKline | 254 (228) | 167 |
| 2 (2) | Pfizer | 213 (182) | 162 |
| 3 (5) | Merck & Co | 211 (167) | 148 |
| 4 (3) | Sanofi-Aventis | 211 (180) | 151 |
| 5 (7) | AstraZeneca | 184 (122) | 137 |
| 6 (4) | Novartis | 175 (177) | 114 |
| 7 (19) | Schering-Plough | 140 (56)* | 89 |
| 8 (9) | Johnson & Johnson | 137 (99) | 76 |
| 9 (6) | Hoffmann-La Roche | 129 (130) | 72 |
| 10 (12) | Bristol-Myers Squibb | 99 (87) | 67 |
| 11 (8) | Wyeth | 99 (110) | 76 |
| 12 (10) | Bayer | 97 (90) | 64 |
| 13 (13) | Eli Lilly | 96 (83) | 65 |
| 14 (11) | Astellas | 90 (88) | 55 |
| 15 (16) | Merck KGaA | 81 (72) | 32 |
| 16 (20) | Takeda | 80 (54) | 40 |
| 17 (14) | Abbott | 78 (75) | 48 |
| 18 (24) | Eisai | 73 (46) | 47 |
| 19 (18) | Amgen | 71 (65) | 53 |
| 20 (15) | Daiichi Sankyo | 67 (73) | 44 |
| 21 (21) | Genzyme | 61 (49) | 42 |
| 22 (13) | Genentech | 59 (47) | 30 |
| 23 (-) | Mitsubishi Tanabe Pharma | 57 (-) | 40 |
| 24 (-) | Boehringer Ingelheim | 51 (37) | 35 |
| 25 (22) | Solvay | 45 (48) | 32 |
| *Plus 66 at Akzo Nobel | |||
| Table 2 - Top 25 companies based on the number of products in their R&D pipelines | |||